Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas.
Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Costaz H, Pautier P, Guillemet C, de la Motte Rouge T, Sabatier R, Classe JM, Petit T, Leblanc E, Marchal F, Colombo PE, Barranger E, Savoye AM, Bosquet L, Ray-Coquard I, Carton M, Colomban O, You B, Rodrigues M
Int J Gynecol Cancer
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Azaïs H, Brochard C, Taly V, Benoit L, Ferron G, Ray-Coquard I, You B, Abadie-Lacourtoisie S, Lebreton C, Venat L, Louvet C, Favier L, Blonz C, Dohollou N, Malaurie E, Dubot C, Kurtz JE, Pujade-Lauraine E, Rouleau E, Leary A, Bats AS, Blons H, Laurent-Puig P
Gynecol Oncol.
46MO What are the predictors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers? Consistent data from two large independent datasets
. Marchetti O. Colomban A. Fagotti F. Blanc-Durand D. Giannarelli A. Carrot C.M. Sassu E. Pujade-Lauraine D. Lorusso G. De Rauglaudre R. Ergasti I.L. Ray-Coquard F.M. Capomacchia P-F. Combe A.I. Apostol G. Ferron U. Malapelle A. Leary G. Scambia B. You
ESMO Open. Volume 9, SUPPLEMENT 5, 103553, June 2024
Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.
Benoit You, Anna Fagotti, Olivier Colomban, Diana Giannarelli, Felix Blanc-Durand, Giovanni Scambia, Aurore Carrot, Domenica Lorusso, Eric Pujade-Lauraine, Raffaella Ergasti, Gaetan De Rauglaudre, Carolina Maria Sassu, Isabelle Laure Ray-Coquard, Filippo Maria Capomacchia, Pierre Combe, Adriana Ionela Apostol, Gwenael Ferron, Umberto Malapelle, Alexandra Leary, Claudia Marchetti
Journal of Clinical Oncology 2024 42:16_suppl, 5560-5560
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA
Aurore Carrot, Stéphane Oudard, Olivier Colomban, Karim Fizazi, Denis Maillet, Oliver Sartor, Gilles Freyer, Benoit You
JCO Clinical Cancer Informatics 2024 :8
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting"
Van Wagensveld L, Colomban O, van der Aa MA, Freyer G, Sonke GS, Kruitwagen RFPM, You B.
J Gynecol Oncol. 2024 May;35(3):e34. doi: 10.3802/jgo.2024.35.e34. Epub 2024 Jan 8. PMID: 38216134; PMCID: PMC11107274
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
Bouvarel B, Colomban O, Frenel JS, Loaec C, Bourgin C, Berton D, Freyer G, You B, Classe JM.
Int J Gynecol Cancer
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, Karamouza E, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A
Eur J Cancer. 2023 Sep
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, Fontaine J, Péron J, Maillet D, Tartas S, Bonnin N, Trillet-Lenoir V, Colomban O, Augu-Denechere D, Freyer G, Tod M
Cancer Chemother Pharmacol
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.
Karamouza E, Glasspool RM, Kelly C, Lewsley LA, Carty K, Kristensen GB, Ethier JL, Kagimura T, Yanaihara N, Cecere SC, You B, Boere IA, Pujade-Lauraine E, Ray-Coquard I, Proust-Lima C, Paoletti X
Cancers (Basel).
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, Guitton J, Schwiertz V, Fontaine J, Peron J, Maillet D, Tartas S, Bonnin N, Colomban O, Augu-Denechere D, Freyer G, You B
Cancer Chemother Pharmacol
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O, Swisher EM, Kristeleit R, McNeish I, Shapira-Frommer R, Goble S, Lin KK, Maloney L, Freyer G, You B
EBioMedicine.
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM
J Clin Oncol. 2023 Jan 1
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study
Colomban, Tod, Leary, Ray-Coquard, Lortholary, Hardy-Bessard, Pfisterer, Du Bois, Kurzeder, Burges, Péron, Freyer, You B
Clin Cancer Res. 2019 Sep 1
Two prognostic populations of ovarian cancer patients defined by CA-125 modeled kinetic parameter KELIM™ (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/ MRC CTU/GCIG trials)
Benoit You, Olivier Colomban, Gilles Freyer, Alexandra Leary, Isabelle Laure Ray-Coquard, Alain Lortholary, Anne Claire Hardy Bessard, Jacobus Pfisterer, Andreas Du Bois, Christian Kurzeder, Alexander Burges, and Michel Tod
Journal of Clinical Oncology 2017 35:15_suppl, 5554-5554
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment
You B, Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M, Colomban O
Annals of Oncology 25: 41–56, 2014
Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements
You B, Harvey R, Henin E, Mitchell H, Golfier F, Savage PM, Tod M, Wilbaux M, Freyer G, Seckl MJ.
Br J Cancer. 2013 May 14;108(9):1810-6.
Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias
You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, Colomban O, Ribba B, Raudrant D, Massardier J, Chabaud S, Golfier F.
Ann Oncol. 2010 Aug;21(8):1643-50.
Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy
You B, Girard P, Paparel P, Freyer G, Ruffion A, Charrié A, Hénin E, Tod M, Perrin P.
Prostate. 2009 Sep 1;69(12):1325-33.